Sana Biotechnology today formally announced that it has raised more than $700 million in venture funding — one of the largest venture financing deals in the life sciences industry and one of the biggest rounds on record in Seattle. “Sana is dedicated to modulating genes in cells as well as replacing damaged cells in the body,” Sana CEO Steve Harr said in a press release.